For research use only. Not for therapeutic Use.
TrxR-IN-5 (compound 4f) is a potent TrxR (thioredoxin reductase) inhibitor, with an IC50 of 0.16 μM. TrxR-IN-5 increases the levels of ROS, thus leading to potent antiproliferative effects. TrxR-IN-5 exhibits prominent anticacer and anti-metastasis effects[1].
TrxR-IN-5 (compound 4f) (MDA-MB-231 xenograft in BALB/c nude mice, 0-25 mg/kg, IP, once) shows strong inhibition potency toward solid tumors of breast cancer in vivo[1].
| Catalog Number | I043506 |
| Synonyms | (6E)-6-[[4-[4-[(Z)-(2-oxocyclohex-3-en-1-ylidene)methyl]phenoxy]phenyl]methylidene]cyclohex-2-en-1-one |
| Molecular Formula | C26H22O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C26H22O3/c27-25-7-3-1-5-21(25)17-19-9-13-23(14-10-19)29-24-15-11-20(12-16-24)18-22-6-2-4-8-26(22)28/h3-4,7-18H,1-2,5-6H2/b21-17-,22-18+ |
| InChIKey | BIAIWJANZKBISX-QGFZOGOGSA-N |
| SMILES | C1CC(=CC2=CC=C(C=C2)OC3=CC=C(C=C3)C=C4CCC=CC4=O)C(=O)C=C1 |
| Reference | [1]. Meng C, et al. Efficacy of novel methylenecyclohexenone derivatives as TrxR inhibitors in suppressing the proliferation and metastasis of human cancer cells. Bioorg Chem. 2020 Dec;105:104360. |
